This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
by Zacks Equity Research
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
Ahead of Solventum (SOLV) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for Solventum (SOLV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Is the Options Market Predicting a Spike in Solventum Stock?
by Zacks Equity Research
Investors need to pay close attention to SOLV stock based on the movements in the options market lately.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
by Zacks Equity Research
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Solventum (SOLV) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Solventum (SOLV) delivered earnings and revenue surprises of 12.61% and 3.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
by Zacks Equity Research
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
SOLV vs. DOCS: Which Stock Is the Better Value Option?
Solventum (SOLV) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Solventum (SOLV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Solventum Partners With SprintRay for Same-Day Dental Restorations
by Zacks Equity Research
SOLV partners with SprintRay to introduce an innovative solution for same-day dental restorations, enhancing efficiency, precision and patient care in digital dentistry.
SOLV Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
SOLV Stock Falls Despite Launch of Clarity Precision Grip Attachments
by Zacks Equity Research
Solventum's Clarity precision grip attachments enhance treatment outcomes for orthodontic patients, reducing the risk of misplaced and malformed attachments.
SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up
by Zacks Equity Research
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. The higher EPS outlook looks promising.
Solventum Q3 Earnings Likely to Reflect Declining Volume Trend
by Zacks Equity Research
SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Veeva Systems Collaborates With Walgreens to Improve Patient Outcomes
by Zacks Equity Research
VEEV partners with Walgreens to provide better patient outcomes to life sciences companies.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
SOLV or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Take the Zacks Approach to Beat the Markets: Phibro Animal Health, Travelzoo, Ollie's Bargain Outlet in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.